Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Inclusion Criteria:
- A diagnosis of multiple myeloma or possible multiple myeloma who will have a bone
marrow biopsy and aspirate
- Planned therapy with standard chemotreatment for multiple myeloma
- Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone
survey available for staging purpose.
- ≥18 years old
Exclusion Criteria:
- < 18 years old
- Patients who will not receive chemotreatment
- Patients whose treatment records are not available
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Measure the expression levels of CXCR4, CD47, and pS6 by flow cytometry in myeloma patient's marrow aspirate
Outcome Description:
Our Aim 1 is to perform a corrective study to measure the expression levels of CXCR4, CD47, and pS6 by flow cytometry in myeloma patient's marrow aspirate and correlate their expression level with patients' treatment responses
Outcome Time Frame:
3 years
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
101565
NCT ID:
NCT01410981
Start Date:
July 2011
Completion Date:
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|---|
| Medical University of South Carolina | Charleston, South Carolina 29425-0721 |
